The UP-Philippine General Hospital acute coronary events at the emergency room registry (UP PGH-ACER)

OBJECTIVES: This study pilots the creation of a clinical registry for all patients admitted for Acute Coronary Syndromes(ACS) at the Philippine General Hospital (PGH) Emergency Room (ER). METHODS: This is a single-institution prospective observational study including all patients >18 years old admitted from September to October 2011 with suspected acute coronary syndromes. Abstraction of chart information using a data collection form was done. Patient's clinical data, medications received, and quality of care indicators were noted. The primary study outcome measure is the completeness of chart data, quality indicators such as door-to-ECG time and door-to-needle time, and the clinical profile of patients with ACS. RESULTS: Thirty patients were included, with equal numbers of males females, and a mean age of 59 years old. There were equal numbers of patients with STEMI (43%) and NSTEMI (43%). The most common risk factor was hypertension (72.4%) followed by smoking (34.48%). Around 20% are diabetics, and 31% have known lipid abnormalities or are on lipid-lowering agents. Around one third of the patients have had previous admissions for acute coronary events. Only two patients had angiographically confirmed CAD. The majority of patients assessed to have acute coronary syndromes (26 patients) were Killip Class I. Only one was cardiogenic shock upon admission. Temporal information such as time of first physician contact and time of drug administration was not available in more than half of the cases. While there is a high rate of physician compliance to guideline recommended therapies, temporal quality indicators sch as door-to-ECG time (2 hours) and door-to-needle time (3.5 hours) remain substandard. The rest of the patients presented beyond 12 hours of chest pain onset and were already chest pain free. Among those who were eligible for thrombolysis, 67% received thrombolytic therapy with streptokinase. No patient was given thrombolytic agent within 30 minutes upon admission to the emergency department. No patient underwent cardiac catheterization as the primary means of revascularization. Hence, door-to-balloon time could not be determined. CONCLUSION: A standardized ACS pathway for adequate documentation of information is necessary for a complete and effective clinical registry for ACS must be set in place. Establishment of an efficient clinical registry must be a joint effort of all services involved in the care for these patients. Proper documentation in clinical charts of patients admitted at the PGH-ER needs to be improved. The quality indicators such as door-to-ECG and door-to-needle time were remarkably above the guideline recommended targets. The compliance for class 1 medications among patients admitted for ACS during the time of the study was optimal.

Chronic heart failure guidelines: A critique

BACKGROUND: Chronic heart failure (HF) disease as an emerging epidemic has a high economic burden, hospitalization, readmission, morbidity rates despite many clinical practice guidelines recommendations. OBJECTIVE: To show that the attributed survival and hospitalization-free event rates in the reviewed chronic HF clinical practice guidelines' Class I-A recommendations as "initial HF drug therapy" is basically "add-on HF drug therapy" to the "baseline HF drug therapy" thereby under-estimating the "baseline HF drug therapy" significant contribution to the clinical outcome. METHODOLOGY: The references cited in the chronic HF clinical practice guidelines of the American Heart Association/American College of Cardiology (AHA/ACC), the Heart Failure Society of America (HFSA), and the European Society of Cardiology (ESC) were reviewed and compared with the respective guidelines' and other countries' recommendations. RESULTS: The "baseline HF drug therapy" using glycosides and diuretics is 79-100% in the cited HF trials. The survival and hospitalization event-free rates attributed to the "baseline HF drug therapy" are 46-89% and 61.8-90%, respectively. The survival and hospitalization-free event rate of the "initial HF drug therapy" is 61-92.8% and 61.8-90%, respectively. Thus the survival and hospitalization event-free rates of the "add-on HF drug therapy" are 0.4-15% and 4.6% to 14.7%, respectively. The extrapolated "baseline HF drug therapy" survival is 8-51% based on a 38% natural HF survival rate for the time period. CONCLUSION: The contribution of "baseline HF drug therapy" is relevant in terms of survival and hospitalization event-free rates compared to the HF Class 1-A guidelines proposed "initial HF drug therapy" which is in essence an "add-on HF drug therapy" in this analysis.